It took less than five years for a CNS drug discovery pact between Evotec SE and Bristol Myers Squibb Company using the German pharma’s novel iPSC platform to bring its first compound to the verge of clinical testing in humans, and further candidates are likely to emerge shortly from the alliance.
Evotec CSO: BMS Opt In On CNS Compound ‘Augurs Well’ For Discovery Pact
Brings Bristol Myers Additional Program Rights In Neurodegenerative Diseases.
Further promising compounds will be explored after Bristol Myers Squibb exercised its option to enter an exclusive license for Evotec’s investigational EVT8683, generated by the German group’s iPSC platform as a potential treatment for neurodegenerative conditions.
More from Business
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.